Thus, we show a novel dichotomous role of NCLX in cancer, where reduced NCLX function lead to reduced tumor growth, while driving a mesenchymal phenotype that leads to increased metastasis and drug resistance. This evidence concerns the gene SLC8B1 and cancer.